Accu-Break Pharmaceuticals, Inc. Announces European Cooperation Agreement with Midas Pharma GmbH

Business Wire, Feb 20, 2008

PLANTATION, Fla. -- Accu-Break Pharmaceuticals, Inc. ("ABP"), a company with a suite of pharmaceutical tablet technologies for creating divisible dosage forms (the "Accu-Break[TM] Technologies") and Midas Pharma GmbH ("Midas"), an independent marketing and distribution company, which supports clients and manufacturing partners regarding all questions concerning Active Pharmaceutical Ingredients, Biosimilars, Custom Synthesis, Contract Manufacture, International Licensing and Pharmaceutical Dossiers, announced today the signing of a cooperation agreement.

Pursuant to the cooperation agreement, the parties will work together to both license the Accu-Break[TM] Technologies to European brand and generic pharmaceutical companies and to develop and market ABP products in Europe. Midas will assist ABP in the introduction, marketing and promotion of the Accu-Break[TM] Technologies to potential collaboration partners. Additionally, Midas may assist ABP in the preparation of regulatory information and in communications with health authorities and European opinion leaders to promote the licensing of the Accu-Break[TM] Technologies.

Allan S. Kaplan, Ph.D., ABP's CEO commented, "This agreement with Midas will help broaden the opportunities available to ABP to license the patented and patent pending Accu-Break[TM] Technologies worldwide." Nigel N. Norton, Executive Director of ABP who leads ABP's international business development group, based in Monaco, added, "ABP and Midas have been working together for a number of months and we are delighted to have formalized this relationship. Through Midas, ABP has already been introduced to a number of interested companies which we hope will result in licensing agreements. We look forward to continuing and further developing our relationship with Midas."

About Accu-Break Pharmaceuticals, Inc.

ABP is developing Accu-Break[TM] Technologies for pharmaceutical tablets. The Company believes that these Accu-Break[TM] Technologies will permit pharmaceutical companies to create pharmaceutical tablets that can be easily divided into precise doses to facilitate dose adjustment and individualized dosing which will enable physicians to better customize treatment for their patients. ABP is located at 1000 S. Pine Island Road, Suite 230, Plantation, FL 33324. The corporate website address is www.accubreak.com.

ABP Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Shareholders are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control. No ACCU-BREAK tablets have been marketed.

Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contacts

Allan S. Kaplan, Ph.D.
CEO
Accu-Break Pharmaceuticals, Inc.
1000 S. Pine Island Road, Suite 230
Plantation, FL 33324
Phone: 954-236-7351
Fax: 954-236-7271
www.accubreak.com
a.kaplan@accubreak.com

Hans Frickel, Ph.D.
Director FPCM & Platform Technologies
Midas Pharma GmbH
Rheinstrasse 49, D-55218 Ingelheim
Phone:  49 (0) 6132 990 153
Fax:  49 (0) 6132 990 653
www.midas-pharma.com